Corporate News Report – Trevi Therapeutics
In the most recent 24‑hour trading window that concluded at 02:43 AM Central Europe on Wednesday, 21 October 2026, the shares of Trevi Therapeutics (TRVI) experienced a modest uptick, rising 0.17 %. At the close of that period, each share was priced at roughly USD 12.83 on major exchanges.
Market Position and Recent Activity
- Shares Outstanding: 142.3 million
- Market Capitalisation: USD 1.70 billion
- 24‑hour Trading Volume: approximately USD 19 million
- Month‑to‑Date Change: a decline of 20.08 % since the close of the previous month
- 200‑Day Simple Moving Average: USD 14.27
- 52‑Week High: USD 20.22 (achieved 17 July 2026)
- 52‑Week Low: USD 9.82 (recorded 19 February 2026)
The modest gain in the latest session is a small counterpoint to a broader decline that has weighed on the company’s shares for several weeks. Investors will be watching the stock’s trajectory relative to its 200‑day moving average, a benchmark often used to gauge medium‑term momentum.
Peer Performance Snapshot
During the same 24‑hour window, several related biotech and medical‑device stocks exhibited varied movements:
| Stock | % Change | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|
| Inspire Medical (INSP) | +1.98 % | USD 71.34 | USD 2 bn | 15.11 |
| Trinity Industries (TRN) | –1.39 % | USD 24.82 | USD 2 bn | 5.94 |
| Sellas Life Sciences I (SLS) | +5.11 % | USD 12.00 | USD 2 bn | – |
| Biocryst (BCRX) | +3.59 % | USD 7.94 | USD 2 bn | – |
| Vera Therapeutics (VERA) | +3.73 % | USD 30.06 | USD 2 bn | – |
While some peers posted gains, Trinity Industries slipped, and Inspire Medical posted a modest rise. The mixed performance across the sector underscores the volatility that can accompany the specialty‑pharma and medical‑device space, particularly for companies with a concentrated pipeline.
Business Focus
Trevi Therapeutics is headquartered in New Haven, United States, and concentrates on developing nalbuphine extended‑release (ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis, as well as levodopa‑induced dyskinesia. By addressing these unmet medical needs, the company aims to carve out a niche in the respiratory and neurological therapeutic arenas.
Prospective investors and analysts can find additional information about the company’s clinical programmes, corporate governance, and financial statements on its website at www.trevitherapeutics.com or by reviewing filings and disclosures on the Nasdaq stock exchange.
